Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BRTX
Here is the to the interview:https://t.co/5epN1TSaQi$BRTX $QQQ
— BenzingaPro (@BenzingaPro) June 27, 2023
$BRTX
.@BioRestorative Therapies $BRTX CEO, Lance Alstodt To Appear On .@Benzinga Live YouTube TV At 12:15 p.m. ET $BRTX $QQQ
— BenzingaPro (@BenzingaPro) June 27, 2023
Got my avg down to $3.05 so I'm pretty happy. Hope everybody stayed the course. I bet on Lance. We still have a gap around $8 to test.
About $5.50 per share for a break even point. Auctus is under SEC scrutiny (see the link a few posts ago), so they are probably being cautious.
Looking good here. Do your own DD... just starting imo
$7 today $10 next
What is the break even point on those converts you mentioned? Thanks
Litigation Release No. 25741 / June 1, 2023
SEC Charges Massachusetts-Based Firm and Its Co-Owners with Acting as Unregistered Securities Dealers
https://www.sec.gov/litigation/litreleases/2023/lr25741.htm
The complaint:
https://www.sec.gov/litigation/complaints/2023/comp25741.pdf
Auctus was the financier through BRTX's bankruptcy, actually got them to change the plan from an asset sale, and they still have about 1.5M shares (preferreds directly convertible into commons), but the PPS has until recently stayed below the break even point.
Bought at 0.0012 brtxq so I'm in the green on my free shares I'm riding. 0.00155 today
Last time I sold was at 0.036... that would be $144 today... and at that point BRTXQ was bc.
I see at least a 200mil mc here.
Gltu
Pretty good flip for those who bought in the 3's, though it's been a pretty low volume walk up. More than it used to trade.
Auctus is now in the green with their 1.5M or so shares, and not sure when that $3.7M offering hit or is going to. Keep an eye on the O/S.
Looking good! 22mil mc this one is just starting!
I had BRTX-100 in the Cayman Islands in October 2022. The real thing, not a placebo. It failed completely. At six months, there is no change in the annular tear, disc bulge, disc height, or hydration. The lumbar disc flared massively from the injection and never fully recovered, so the symptoms are slightly worse now than before.
Before and after (6 month) MRIs:
https://ibb.co/WpzWhRP
https://ibb.co/PCkvBcH
To be clear, I still think this treatment will work for a lot of people, but it definitely didn’t work for me. It shows you how far from a sure thing this is.
I see some news about trial progress coinciding with the $3.7M offering the company issued a prospectus for:
https://ih.advfn.com/p.php?pid=nmona&article=90771547
PPS is in the arena Auctus needed for their 1.5M shares, so watch the O/S.
$BRTX
https://www.biorestorative.com/ir/
April2023 presentation
https://www.biorestorative.com/ir/wp-content/uploads/2023/04/Investor_Presentation_April_2023.pdf
3M Float Nasdaq stock:
https://www.otcmarkets.com/stock/BRTX/security
19,5M market cap / 5,19 stock value = 3.7M float
On May 8th we entered in a partnership with them:
https://www.northwell.edu/
$BRTX market cap is 16,5mil dollar... even in bk this was much much more...
Stock is up 25%+ since their funding and enrollment notice a few weeks ago.
Chart is setting up for a nice move from $5.00 here.
Well, looks like LANCE was right after all!
GO BRTX without a Q LOL
Time to reach 5$ after rs folks? $BRTX Nasdaq gem.
I know right? Of course there’s that pesky 4000/1 split.
Sweet, need another $12 pps to break even, lol
Nice to see things are moving along with a slow climb.
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has completed enrollment for the safety run-in component of its Phase 2 clinical study of BRTX-100 targeting patients suffering from chronic lumbar disc disease (cLDD).
BRTX-100 is the Company’s lead clinical candidate, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. BRTX-100 is currently being evaluated in connection with a Phase 2 clinical trial to treat cLDD. The trial is prospective, randomized, double-blinded and controlled. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 clinical sites in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.
What a joke , nice find
Missed this prospectus to sell $3.7M of stock...
https://ih.advfn.com/p.php?pid=nmona&article=90771547
Didn't know they needed cash.
$BRTX BioRestorative Therapies Inc. on Stem Cell Therapies to Help Patients ...
And there, you have it... the O/S of about 3.7M turns over nearly 10X's in a day at 35M shares traded vs day prior volume of 2000, day before that 1400... more sells than buys, but the PPS is up 29%.
Sounds legit... no manipulation here...
Been a long time coming.
Nice to see them lining up the ducks.
No, it is purely automation. You don't turn the O/S over 6-7X's in just over an hour. Someone wants to sell stock and hired some wash trading robots or a trading group to help.
No, it's trades ...
I see they've turned on the wash trading robots. Nearly 100k trades so far, equal buys and sells, stock PPS up 50%, already tossed the O/S over 6X's. This is the market manipulation folks should be concerned about, whole new set of bagholders.
Here's the opportunity to escape while a large holding is being eased into the market. They'll turn the robots off in a few days.
BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
Source: GlobeNewswire Inc.?
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program. The notice of allowance was issued on February 24, 2023.
This will be the third patent granted under this particular family of intellectual property, claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes that have been derived from human brown adipose-derived stem cells. Therapeutic benefits of using brown adipose have been demonstrated in various models and may provide a valuable therapeutic tool for treating a range of metabolic disorders. In addition, BioRestorative is evaluating the use of this technology to target indications outside of metabolic disorders.
“This is the second notice of allowance we have received regarding our ThermoStem® program within 2023. This notice of allowance is very meaningful as it provides the Company with further protection and strengthens our technology as we develop and expand into the clinic. Additionally, it enhances our ability to engage with the strategic community on collaborative and partnering opportunities” said Lance Alstodt, the Company’s CEO.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Email: ir@biorestorative.com
?
?
They have hardly updated anyone on anything. I'm surprised Auctus hasn't been on them being completely illiquid.
over 2 years ago..i had 5.5 millions shares and coulf have made 200k profit..but I was greedy..and held on to 4000-1 RS.Big mistake..now I sold 1000 of my 2000 shares today..and bought a much more stock thats ready to go on a 5X plus run..Cant wait to swing that and buy more BRTX back ..Mka...Make that dead money in BRTX work for ya till Trials for BRTX-100 are in phaze 2...BRTX wont go up more than to $6 bucks in 6 months..Lance does not care about old shareholders..just new ones..LOL..but BRTX is still going to be a $20 buck plus stock but im still down 20 K ..Should have sold for profit..now wait forever for nickles ..must put in 10 k now so ill play this other soon to be runner!.BRTX still will reward at this price ..but in 1-4 years..
Any reason to buy bullish on this stock? By default I am bearish...
BRTX was all the rage many years ago.
What is it doing now?
$BRTX BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program https://ih.advfn.com/stock-market/NASDAQ/biorestorative-therapies-BRTX/stock-news/90178116/biorestorative-therapies-announces-notice-of-allow
I think safety data comes out next. Hopefully all good. Then I'm looking for big pharma to get interested. Lots of buying by management is a good thing !!!
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies $BRTX https://www.benzinga.com/general/biotech/23/01/30566249/2022-was-a-year-of-growth-funding-and-positive-results-for-biorestorative-therapies via @Benzinga
This was a good bankruptcy play , that was about it .
Guys I'm still with you at 5.60 after the 1:4000
$BRTX it's my first OTC lead to Nasdaq
hope the current pipeline will drive us to 100$....
The reason the company is run by dishonest people is that the patents aren’t worth as much as you think. The treatment is too expensive, doesn’t fit into the third-party payer healthcare system, doesn’t work reliably, and has too much competition.
I Saw enough of LA and Silvas Scruples with the 4000-1 RS 2 years ago to have a lasting impression. LOL....but now I trust the patents are still worth alot more than 3 bucks a share.Trust the Ticker..We have to wait 2-5 years to see nice money..$60 pps..but in still love BRTX ..Patience is an understatement here to have to catch this stock again..but WE Will!
I had the BRTX treatment in the Cayman Islands in October. So far (12 weeks out), the effect is underwhelming. It’s still early, so more improvement might come down the line. But it doesn’t surprise me at all that this has so much difficulty getting trial funding. It doesn’t work consistently except for a very specific type of disc pathology, and might fail the trial.
Francisco Silva, the head scientist for BioRestorative, took the hypoxic / platelet lysate culture protocol and started using it at a stem cell gimmick clinic in Tijuana called Cellular Performance Institute, and did so without properly sublicensing it from BioRestorative, which undoubtedly provoked the ire of Regenexx. This agreement is likely about avoiding litigation over that. It also proves that Silva lacks scruples.
So, how's the trial going? Anybody know?
You'd think they'd have updated their shareholders by now.
Slow but steady!
It's nice seeing a company CEO actually buying shares, even if it's only 400 at a time...LOL
$BRTX CEO purchased 400 shares at $3.11 for a total of $1,244. ALSTODT LANCE now owns 186,521 shares.
https://www.ceo-buys.com/search?tickers=BRTX
BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event https://www.newsfilecorp.com/release/151548/BioRestorative-Therapies-to-Present-in-The-Jan-26th-Virtual-Investor-Summit-Microcap-Event #NASDAQ #Investing $BRTX
$BRTX EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome https://finance.yahoo.com/news/exclusive-biorestorative-secures-funding-support-113115485.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
Correct.
Followers
|
481
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
63377
|
Created
|
11/16/07
|
Type
|
Free
|
Moderators |
We will need to obtain a significant amount of financing to initiate and complete our clinical trials and implement our business plan.
Since our inception, we have not generated revenues from our operations and have funded our operations through the sale of our equity securities and debt securities. The implementation of our business plan, as discussed in this prospectus under the caption “Business,” will require the receipt of sufficient equity and/or debt financing to purchase necessary equipment, technology and materials, fund our clinical trials and other research and development efforts and otherwise fund our operations. We anticipate that we will require approximately $12,000,000 in financing to complete a Phase 2 clinical trial using BRTX-100. We anticipate that we will require approximately $45,000,000 in further additional funding to complete our clinical trials using BRTX-100 (assuming the receipt of no revenues). We will also require a substantial amount of additional funding to implement our other programs described in this prospectus under the caption “Business,” including our metabolic ThermoStem Program, and fund general operations. The net proceeds of this offering will not be sufficient to satisfy the foregoing needs. No assurance can be given that the anticipated amounts of required funding are correct or that we will be able to accomplish our goals within the timeframes projected. In addition, no assurance can be given that we will be able to obtain any required financing on commercially reasonable terms or otherwise. In the event we do not obtain the financing required for the above purposes, we may have to curtail our development, marketing and promotional activities, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately we could be forced to discontinue our operations and liquidate.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |